Business Card for Richard Levy, M.D.:


Executive Vice President, Chief Drug Developme
 Wilmington, DE area
Email Avail: 3 Day Free Trial


1801 Augustine Cut-Off
Wilmington, DE 19803
Tel: (302) 498-6700

Last updated on 2017-11-14

About Richard Levy, M.D.:

Richard Levy, M.D. works as an Executive Vice President, Chief Drug Developme for Incyte at Wilmington, DE. The company's webpage is http://www.incyte.com. For email, phone number and executive profiles for Executive Vice President, Chief Drug Developme and other executives of Incyte at Wilmington, DE, check Incyte at Joesdata.com. Not the Richard Levy, M.D. you are looking for? Do a quick search in our website and find other people named Richard Levy, M.D..
Richard Levy, M.D.'s Work History:
No information available..

Richard Levy, M.D.'s Education:
No information available..

Richard Levy, M.D.'s Co-workers:
As of August 18, 2022, Richard Levy, M.D. has 224 co-workers under the company name Incyte at Joesdata.com.

About Incyte:

Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. In November 2011, JAKAFI bec...... (Source: SEC reports)

Company News:
2018-09-13 17:30:37
In Honor of MPN Awareness Day and Blood Cancer Awareness Month, Incyte Debuts Documentary Spotlighting Myeloproliferative Neoplasms (MPNs)
2018-09-13 17:30:33
Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
2018-09-13 17:06:17
In Honor of MPN Awareness Day and Blood Cancer Awareness Month, Incyte Debuts Documentary Spotlighting Myeloproliferative Neoplasms (MPNs)
2018-09-11 17:30:44
Incyte and Foundation Medicine Announce Agreement to Develop Companion Diagnostic for Pemigatinib (INCB54828), a Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
2018-09-11 17:06:27
Incyte and Foundation Medicine Announce Agreement to Develop Companion Diagnostic for Pemigatinib (INCB54828), a Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
2018-09-06 17:30:47
Incyte Announces Chief Financial Officer David Gryska to Retire at the End of 2018
2018-09-06 17:02:21
Incyte Announces Chief Financial Officer David Gryska to Retire at the End of 2018
2018-08-28 18:54:24
Incyte to Present at Upcoming Investor Conference
2018-08-28 17:31:00
Incyte to Present at Upcoming Investor Conference
2018-07-31 17:30:29
Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs

People in the same industry: